OverviewSuggest Edit

Roivant Sciences is a tech-enabled healthcare company focused on completing the development of late-stage drug candidates with the potential to improve the lives of patients and their families. It also develops healthcare technologies through subsidiaries such as Datavant, which helps healthcare institutions share and aggregate data, and Lokavant, which integrates clinical trial data sources to identify and mitigate risks in drug development.

HQNew York, NY, US

Latest Updates

Employees (est.) (Jun 2021)275(+5%)
Job Openings20
Cybersecurity ratingBMore

Key People/Management at Roivant Sciences

Vivek Ramaswamy

Vivek Ramaswamy

Founder & CEO
Mayukh Sukhatme

Mayukh Sukhatme

Chief Investment Officer & President
Frank Torti

Frank Torti

Vant Chair
Jo Chen

Jo Chen

General Counsel
Benjamin Zimmer

Benjamin Zimmer

Matthew Gline

Matthew Gline

Show more

Roivant Sciences Office Locations

Roivant Sciences has offices in New York and Basel
New York, NY, US (HQ)
151 W 42nd St 15th Floor
Basel, CH
Viaduktstrasse 8
Show all (2)

Roivant Sciences Financials and Metrics

Summary Metrics

Founding Date


Roivant Sciences total Funding

$1.9 b

Roivant Sciences latest funding size

$200 m

Time since last funding

3 years ago

Roivant Sciences investors

Roivant Sciences's latest funding round in November 2018 was reported to be $200 m. In total, Roivant Sciences has raised $1.9 b. Roivant Sciences's latest valuation is reported to be $7 b.
View all funding rounds

Roivant Sciences Revenue

Market valuation

Show all financial metrics

Roivant Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Dermavant Sciences

Roivant Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Roivant Sciences Online and Social Media Presence

Embed Graph

Roivant Sciences Company Culture

  • CEO Rating



Learn more on Comparably

Roivant Sciences News and Updates

Roivant Sciences Strikes SPAC Deal Valuing The Drug Company At $7.3 Billion

Vivek Ramaswamy, founder of Roivant, is teaming up with Jim Momtazee's Patient Square Capital.

Roivant Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference

NEW YORK and BASEL, Switzerland, Jan. 8, 2021 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of recent milestones and future directions for the business at the 39th Annual J.P. Morgan...

Roivant Sciences Continues its Partnership With BaseLaunch for Phase II

BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that Roivant Sciences has joined as the third partner of BaseLaunch Phase II, the next phase in BaseLaunch's company building activities. Roivant Sciences has already been a partner in the first Phase of Bas…

Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL200

Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic-resistant staphylococci. This licensing deal is worth a total of US$667.5M inc…

Roivant Sciences Announces $200 Million Investment Round

Roivant Sciences today announced a $200 million equity financing. New investors include NovaQuest Capital Management, RTW Investments, and other large institutional asset managers. These new investors comprise a majority of the round. All existing institutional shareholders in Roivant are also parti…
Show more

Roivant Sciences Blogs

Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis

Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action PSOARING 1 and PSOARING 2 are Two Identical Phase 3 Clinical Trials that have Enrolled a Combined 1,025 Patients to Evaluate the Safety and Efficacy of Tapinarof in Adult Patients with Plaque Psoriasis Derma…

Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients Emerging clinical evidenc e in COVID-19 patients suggests that GM-CSF contributes to immunopathology caused by SARS CoV-2 in patients with or at risk of developing ARDS …

Symphony Health Partners with Datavant for the Industry’s Deepest View of the Patient Journey

March 11, 2020 – PRA Health Sciences, the owner and operator of Symphony Health, today announced a partnership between Symphony Health and Datavant that allows life sciences companies to build fit-for-purpose data assets and strategies to support the development and delivery of new drugs. Datavant c…

Datavant Announces Privacy, Security, and Public Policy Leadership Team Expansion

Datavant has hired Aden Fine as General Counsel and Chief Privacy Officer  Datavant has hired Dongting Yu, PhD, as Head of Security Engineering David Shulkin (former Secretary of Veterans Affairs) and Andrew von Eschenbach (former FDA Commissioner and NCI Director) appointed to Datavant Advisory Boa…

Dermavant Appoints Chris Chapman as Chief Commercial Officer

Over 20 years of leadership experience in the biopharmaceutical industry Former Vice President and General Manager, U.S. Prescription Business for Galderma Former Head of Pfizer’s U.S. Pharmaceutical Contracting and Pricing Organization Dermavant expects Phase 3 data for tapinarof in 2020 LONG BEACH…

Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen NEW Y…
Show more

Roivant Sciences Frequently Asked Questions

  • When was Roivant Sciences founded?

    Roivant Sciences was founded in 2014.

  • Who are Roivant Sciences key executives?

    Roivant Sciences's key executives are Vivek Ramaswamy, Mayukh Sukhatme and Frank Torti.

  • How many employees does Roivant Sciences have?

    Roivant Sciences has 275 employees.

  • Who are Roivant Sciences competitors?

    Competitors of Roivant Sciences include Samumed, Ironwood Pharmaceuticals and SciClone Pharmaceuticals.

  • Where is Roivant Sciences headquarters?

    Roivant Sciences headquarters is located at 151 W 42nd St 15th Floor, New York.

  • Where are Roivant Sciences offices?

    Roivant Sciences has offices in New York and Basel.

  • How many offices does Roivant Sciences have?

    Roivant Sciences has 2 offices.